ZimVie Announces Completion of its Acquisition by ARCHIMED
ZimVie (NASDAQ: ZIMV) announced on Oct 20, 2025 that ARCHIMED completed its previously announced acquisition, and ZimVie is now a privately held company.
Under the transaction terms announced July 20, 2025, ARCHIMED acquired all outstanding ZimVie shares for $19.00 in cash per share. As a result, ZimVie common stock no longer trades on the NASDAQ. Financial and legal advisors to the transaction were disclosed for both parties.
ZimVie (NASDAQ: ZIMV) ha annunciato il 20 ottobre 2025 che ARCHIMED ha completato l'acquisizione precedentemente annunciata e ZimVie è ora una società privata.
Secondo i termini dell'operazione comunicati il 20 luglio 2025, ARCHIMED ha acquisito tutte le azioni ZimVie in circolazione per 19,00 USD in contanti per azione. Di conseguenza, le azioni ordinarie ZimVie non sono più negoziate sul NASDAQ. I consulenti finanziari e legali per l'operazione sono stati resi noti per entrambe le parti.
ZimVie (NASDAQ: ZIMV) anunció el 20 de octubre de 2025 que ARCHIMED completó la adquisición previamente anunciada y que ZimVie ahora es una empresa privada.
De acuerdo con los términos de la transacción anunciados el 20 de julio de 2025, ARCHIMED adquiría todas las acciones en circulación de ZimVie por 19,00 USD en efectivo por acción. Como resultado, las acciones ordinarias de ZimVie ya no cotizan en la NASDAQ. Los asesores financieros y jurídicos de la transacción fueron divulgados para ambas partes.
ZimVie (NASDAQ: ZIMV)는 2025년 10월 20일 ARCHIMED가 앞서 발표한 인수를 완료했고 ZimVie가 이제 비상장 기업임을 발표했습니다.
2025년 7월 20일에 발표된 거래 조건에 따르면 ARCHIMED는 ZimVie의 모든 발행 주식을 주당 미화 19.00달러의 현금으로 인수했습니다. 그 결과 ZimVie의 보통주는 더 이상 NASDAQ에서 거래되지 않습니다. 거래에 대한 재무 및 법률 자문은 양측에 대해 공개되었습니다.
ZimVie (NASDAQ: ZIMV) a annoncé le 20 octobre 2025 que ARCHIMED a terminé l'acquisition annoncée précédemment et que ZimVie est désormais une société privée.
Selon les termes de la transaction annoncés le 20 juillet 2025, ARCHIMED a acquéri toutes les actions en circulation de ZimVie pour 19,00 USD en numéraire par action. En conséquence, l'action ordinaire ZimVie n'est plus cotée sur le NASD AQ. Les conseillers financiers et juridiques de la transaction ont été divulgués pour les deux parties.
ZimVie (NASDAQ: ZIMV) gab am 20. Oktober 2025 bekannt, dass ARCHIMED die zuvor bekannt gegebene Übernahme abgeschlossen hat und ZimVie nun ein privat gehaltenes Unternehmen ist.
Nach den am 20. Juli 2025 bekannt gegebenen Transaktionsbedingungen erwarb ARCHIMED alle ausstehenden ZimVie-Aktien für 19,00 USD Barwert je Aktie. Infolgedessen wird das ZimVie-Stammaktien nicht mehr an der NASDAQ gehandelt. Finanz- und Rechtsberater der Transaktion wurden für beide Parteien bekannt gegeben.
ZimVie (NASDAQ: ZIMV) أعلنت في 20 أكتوبر 2025 أن ARCHIMED أكملت الاستحواذ المعلن سابقاً، وأن ZimVie أصبحت الآن شركة خاصة.
وفقاً لشروط الصفقة المُعلنة في 20 يوليو 2025، استحوذت ARCHIMED على جميع الأسهم القائمة من ZimVie مقابل 19.00 دولاراً أمريكياً نقداً للسهم الواحد. ونتيجة لذلك، لم تعد أسهم ZimVie العادية مدرجة في NASDAQ. تم الكشف عن المستشارون الماليون والقانونيون للصفقة لكلا الطرفين.
ZimVie (NASDAQ: ZIMV) 于 2025年10月20日宣布，ARCHIMED 已完成此前宣布的收购，ZimVie 现为一家私有公司。
根据 2025年7月20日 公布的交易条款，ARCHIMED 以每股 19.00 美元现金 收购了 ZimVie 的所有流通在外普通股。因此，ZimVie 普通股不再在 NASDAQ 上交易。交易的财务与法律顾问已向双方披露。
- $19.00 cash per share paid to ZIMV shareholders
- Acquirer focused exclusively on healthcare
- Completion delivers immediate liquidity to shareholders
- ZIMV common stock no longer trades on NASDAQ
- Shareholders lose ongoing public market price discovery
ZimVie Inc. Becomes Privately Held Company
PALM BEACH GARDENS, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (“ZimVie”), a global life sciences leader in the dental implant market, today announced that ARCHIMED, an investment firm focused exclusively on healthcare industries, has completed its previously announced acquisition of ZimVie.
Pursuant to the terms of the transaction announced on July 20, 2025, ARCHIMED acquired all of the outstanding shares of ZimVie stock. ZimVie stockholders are entitled to receive
“We are excited to partner with ZimVie to accelerate its growth as a global leader in the dental implant market,” said André-Michel Ballester, Managing Partner at ARCHIMED. “ZimVie’s proven innovation, trusted brand, and strong clinical heritage align perfectly with ARCHIMED’s mission to support world-class healthcare companies.”
Centerview Partners served as exclusive financial advisor to ZimVie, and Cravath, Swaine & Moore LLP served as legal advisor. UBS Investment Bank served as exclusive financial advisor to ARCHIMED, and Latham & Watkins LLP served as legal advisor.
About ZimVie
ZimVie is a global life sciences leader in the dental implant market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at www.ZimVie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram.
About ARCHIMED
With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages
Media Contact Information:
ARCHIMED
Stéphanie Du Ché • stephanie.duche@archimed.group
(+33) 6 16 36 11 08
ZimVie
Grace Flowers • Grace.Flowers@ZimVie.com
(561) 319-6130
Investor Contact Information:
Gilmartin Group LLC
Webb Campbell • Webb@gilmartinir.com
FAQ
What did ZimVie announce on October 20, 2025 regarding ZIMV stock?
How much cash will ZIMV shareholders receive per share from ARCHIMED?
When did ARCHIMED complete the acquisition of ZimVie (ZIMV)?
Will ZimVie continue trading under the ticker ZIMV after the deal?
Who advised ZimVie and ARCHIMED on the transaction announced Oct 20, 2025?
